Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Restore Vision
Tokyo, Japan
A
1-10 Employees
2016
Key takeaway
Restore Vision is a Japanese startup focused on developing gene therapy for visual restoration, which directly aligns with the concept of in vivo gene therapy.
Reference
Core business
株式会社レストアビジョン
Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.
AceRNA
Kyoto, Japan
A
1-10 Employees
2018
Key takeaway
The company is a biotech startup dedicated to creating innovative genetic therapies that specifically target disease-causing cells, aiming to minimize patient burden. They are particularly focused on developing advanced treatments using RNA Switches.
Reference
Core business
News - aceRNA
aceRNA
ReproCELL
Yokohama, Japan
A
51-100 Employees
2003
Key takeaway
REPROCELL offers the AteloGene In Vivo siRNA/miRNA Quick Gelation Transfection Kit, designed for efficient in vivo transfection of siRNA and microRNA. This product enhances translational research efforts, particularly in gene therapy applications.
Reference
Product
[KKN-1494] AteloGene In Vivo siRNA/miRNA Quick Gelation Transfection Kit (Local Use)
Purchase the AteloGene In Vivo siRNA/miRNA Quick Gelation Transfection Kit (Local Use) from REPROCELL (KKN-1494). Request a quote for delivery to the USA or Europe today.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
AccuRna
Tokyo, Japan
A
1-10 Employees
2015
Key takeaway
AccuRna is focused on advancing drug delivery systems for nucleic acid therapeutics, including mRNA, which is crucial for in vivo gene therapy. Their commitment to developing safe and efficient delivery methods aims to provide innovative treatments for patients with refractory diseases.
Reference
Product
Therapeutic Vaccine – AccuRna, Inc.
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
T Cell Nouveau Inc. is advancing in the field of gene therapy with its innovative Hybrid CAR T-cell therapy, which aims to significantly enhance the treatment of solid tumors. This approach represents a major advancement over traditional CAR and TCR-T cell therapies.
Reference
Product
Technology | T Cell Nouveau Inc.
CAR-T細胞治療 自己由来CAR-T細胞治療
Minaris Regenerative Medicine
Tokyo, Japan
A
501-1000 Employees
-
Key takeaway
Minaris Regenerative Medicine specializes in the development and manufacturing of cell and gene therapy products, highlighting their expertise and commitment to quality in this innovative field. Their state-of-the-art facilities and experience position them as a key player in providing therapies that could be relevant for in vivo gene therapy applications.
Reference
Service
QP Batch Certification | Minaris Regenerative Medicine
For cell and gene therapy products manufactured outside the European Union, Minaris Regenerative Medicine offers batch release to the EU market by Qualified Persons (QP).
GeneFrontier Japan
Sakai, Japan
A
- Employees
2010
Key takeaway
The company specializes in innovative solutions for protein engineering and biologics, which may be relevant to the development of in vivo gene therapy approaches. Their expertise in antibody drugs and new biopharmaceuticals could contribute to advancements in therapeutic strategies.
Reference
Product
Drug Discovery | 日本語版
NEXTGEM INC.
Tokyo, Japan
A
11-50 Employees
2016
Key takeaway
The company, Nexgen, is involved in in vivo gene therapy, specifically focusing on LT-HSC-based gene therapy (NGH-204). They utilize their technology to isolate and expand genetically abnormal hematopoietic stem cells ex vivo.
Reference
Product
ヒト長期造血幹細胞の遺伝子治療 LT-HSC- based gene therapy(NGH-204) - ネクスジェン株式会社
先天的に異常のある造血幹細胞を生体外に取り出し、当社の保有する技術を活かしLT-HSCの単離、及び生体外で増幅
Red Arrow Therapeutics
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
Red Arrow Therapeutic is a biotech startup focused on developing innovative drug delivery systems using nanotechnology, which could be relevant to advancements in in vivo gene therapy.
Reference
Core business
HOME | Red Arrow Theraputic
ThinkCyte
Tokyo, Japan
A
11-50 Employees
2016
Key takeaway
The company is focused on advancing innovative therapies and diagnostics, particularly in cell therapy. Their novel Ghost Cytometry technique enables label-free characterization and isolation of cells at high throughput, which is crucial for enhancing the efficiency of cell therapy processes.
Reference
Product
Cell Therapy - ThinkCyte
Label-free Monitoring and Isolation of Target Cells Our Solution for Cell Therapy Conventionally, surface markers or stains have been necessary to characterize and isolate target cells in the cell therapy manufacturing process. By applying Ghost Cytometry, we perform label-free characterization and isolation of cells at high throughput by using machine predicted “in-silico” labels. Our technology can classify and isolate cells based on morphological differences and has been used for identifying live and dead cells, activated and resting T cells, and differentiated and undifferentiated stem cells. It has also been used to assess more subtle morphological variations in cells and organelles including cell-cycle phases, glycolytic levels, and apoptotic status. This technology … Continued
Technologies which have been searched by others and may be interesting for you:
In the In Vivo Gene Therapy industry in Japan, several key considerations are crucial for those researching companies in this field. Regulatory frameworks are stringent, governed by the Pharmaceuticals and Medical Devices Agency (PMDA), which oversees clinical trials and product approvals. Understanding these regulations is essential, as they can significantly impact the timeline and feasibility of therapy development. Additionally, the industry faces challenges such as high research and development costs and the complexity of delivery mechanisms for gene therapies. Opportunities exist in Japan due to its advanced healthcare infrastructure and a high prevalence of genetic disorders, which create demand for innovative therapies. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, emphasizing the importance of identifying market players and their unique offerings. Environmental concerns, although less prominent than in other sectors, still play a role in manufacturing and waste management practices related to gene therapies. Lastly, the global market relevance is increasing, driven by Japan's collaborative efforts with international research and development initiatives, positioning it as a significant player in the global gene therapy market. Overall, thorough research on these aspects can provide valuable insights for anyone interested in entering this dynamic industry.
Some interesting numbers and facts about your company results for In Vivo Gene Therapy
| Country with most fitting companies | Japan |
| Amount of fitting manufacturers | 32 |
| Amount of suitable service providers | 19 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2003 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for In Vivo Gene Therapy
What are related technologies to In Vivo Gene Therapy?
Based on our calculations related technologies to In Vivo Gene Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of In Vivo Gene Therapy?
Start-Ups who are working in In Vivo Gene Therapy are T Cell Nouveau, Red Arrow Therapeutics
Which industries are mostly working on In Vivo Gene Therapy?
The most represented industries which are working in In Vivo Gene Therapy are Other, Biotechnology, Medical, IT, Software and Services, Pharmaceuticals
How does ensun find these In Vivo Gene Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.